Cymabay Therapeutics Inc

NASDAQ: CBAY
$32.48
+$0.00 (+0.0%)
Closing price April 1, 2024

CBAY Chart and Intraday Price

CBAY Company Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Sector LIFE SCIENCES
Industry PHARMACEUTICAL PREPARATIONS
Address 3876 BAY CENTER PLACE, HAYWARD, CA, US
Fiscal Year End December
Latest Quarter 12/31/2023
Market Cap 3,699.52M USD
Shares Outstanding 114,785,000
Cymabay Therapeutics Inc is a biopharmaceutical company in the clinical stage, dedicated to developing therapies aimed at liver and chronic diseases. Its flagship product, seladelpar, targets primary biliary cholangitis, a liver disease, through a specific receptor activation. Additionally, Cymabay is working on a treatment for type 1 diabetes. Originally known as Metabolex, Inc., the company was founded in 1988 and is based in Fremont, California.

CBAY Articles

Tuesday's top analyst upgrades and downgrades included Amgen, CF Industries, Coterra Energy, CymaBay Therapeutics, Eaton, Marriott, Monster Beverage, Mosaic, Nutrien, Public Service Enterprise, Urban...
Friday's top analyst upgrades and downgrades included Advanced Micro Devices, Asana, Etsy, Exact Sciences, Guardant Health, Hilton Worldwide, Meta Platforms, MongoDB, Salesforce, ServiceNow, Sysco...
Wednesday's top analyst upgrades and downgrades included Bluebird Bio, Boeing, Coinbase Global, Costco Wholesale, Envista, Merck, New Fortress Energy, NexTier Oilfield Solutions, Radius Global...
These are five biotech and medtech stocks for very aggressive accounts that look to get shares count leverage on companies that have sizable upside potential.
CymaBay Therapeutics posted a huge gain to start off the week after the company reported results from a late-stage clinical study for the treatment of primary biliary cholangitis.
CymaBay Therapeutics shares more than doubled on Tuesday after the company announced its first-quarter results, along with a corporate update.